Mirae Asset Global Investments Co. Ltd. trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 12.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 65,572 shares of the biopharmaceutical company's stock after selling 9,597 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of Alnylam Pharmaceuticals worth $10,707,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ALNY. UMB Bank N A MO acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter worth about $28,000. KRS Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $37,000. CKW Financial Group boosted its holdings in Alnylam Pharmaceuticals by 50.0% in the 1st quarter. CKW Financial Group now owns 300 shares of the biopharmaceutical company's stock worth $51,000 after buying an additional 100 shares during the last quarter. Finally, Nauset Wealth Management. LLC acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter worth about $75,000. 93.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ALNY. Royal Bank of Canada lifted their price objective on Alnylam Pharmaceuticals from $225.00 to $250.00 and gave the stock an "outperform" rating in a report on Tuesday. William Blair initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, June 7th. They issued an "outperform" rating on the stock. BMO Capital Markets raised their target price on shares of Alnylam Pharmaceuticals from $192.00 to $200.00 and gave the stock a "market perform" rating in a research note on Friday, September 9th. Chardan Capital lifted their price target on shares of Alnylam Pharmaceuticals from $200.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, August 4th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $222.00 price target (down previously from $225.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 9th. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $232.06.

Alnylam Pharmaceuticals Stock Down 1.8 %

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The business had revenue of $224.80 million during the quarter, compared to analyst estimates of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The business's revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the firm earned ($1.61) EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -8.13 EPS for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,841 shares of the business's stock in a transaction on Friday, August 5th. The shares were sold at an average price of $218.16, for a total value of $401,632.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 5,349 shares of company stock worth $1,033,073 over the last 90 days. Corporate insiders own 1.40% of the company's stock.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Recommended Stories

• Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
• 3 Airline Stocks Stuck in a Holding Pattern
• Roku Stock is Down but Not Out
• If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
• Is Ford Rolling To A Rebound After Its Q3 Warning
• Has AMD stock stock fallen too far?

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.